The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation
|ClinicalTrials.gov Identifier: NCT01336335|
Recruitment Status : Unknown
Verified July 2010 by University of Sao Paulo.
Recruitment status was: Active, not recruiting
First Posted : April 15, 2011
Last Update Posted : April 15, 2011
|Condition or disease||Intervention/treatment||Phase|
|Radionuclide Imaging (MIBG Scintigraphy) Exercise Test Blood Pressure Monitoring, Ambulatory Sympathetic Nerve Activity Catecholamines||Device: CPAP||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effects of Continuous Positive Airway Pressure (CPAP) on Sympathetic Activity in Different Sites of Activation|
|Study Start Date :||July 2010|
|Estimated Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||July 2011|
OSA treatment with CPAP
No Intervention: control
- improvement in sympathetic activity in muscle sympathetic nerve activity (MSNA) [ Time Frame: 3 months ]Improvement in MSNA will be quantified as burst frequency over time (bursts per minute) and as burst frequency corrected for heart rate values (bursts per 100 heartbeats)in the begining and after 3 months.
- improvement in sympathetic activity evaluated in different sites of activation [ Time Frame: 3 months ]
All measurement will be performed at the begining and after 3 months. Blood: blood and 24 hour urine will be collected for norepinephrine quantification.
Heart: Early (15 min) and delayed (3 hr) planar images will be taken after injection of (123)I-MIBG. The mean counts of the whole heart and the mediastinum will be obtained to calculate heart-to-mediastinum count ratios from the early images (H/Me) and from the delayed images (H/Md) and the myocardial washout rate (WR).
Blood pressure: 24 hour ambulatory blood pressure monitoring and blood pressure during exercise test (treadmill test)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01336335
|São Paulo, Brazil|
|Principal Investigator:||Rodrigo Pedrosa, MD, PhD||Heart Institute (InCor)|